SABCS 2023 | How can we best sequence ADCs in breast cancer?

Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, comments on unanswered questions relating to the sequential use of antibody-drug conjugates (ADCs) in patients with breast cancer. Additional prospective research is needed to assess the utility of administering ADCs with varying payloads such as trastuzumab emtansine after trastuzumab deruxtecan, a TOPO1 inhibitor. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.